Lento Bio is focused on developing innovative small molecule eyedrops aimed at treating presbyopia, a condition associated with aging that affects lens flexibility. The company's primary goal is to enhance lens flexibility through these eyedrops, potentially eliminating the need for corrective lenses. This approach represents a significant advancement in addressing age-related vision issues, positioning Lento Bio at the forefront of rejuvenation medicine and biotechnology.

To support its research and development efforts, Lento Bio has relocated to a new facility in Syracuse, NY, as part of Ichor Life Sciences' biotech incubator. This strategic move not only provides access to state-of-the-art resources but also integrates Lento Bio into a growing biotech ecosystem, fostering collaboration with academic institutions and other startups. The company aims to leverage this supportive environment to accelerate the clinical development of its presbyopia treatment and explore additional avenues for repairing long-lived protein damage associated with chronic diseases of aging.

United States

Lento Bio was formed in 2022 in partnership with Ichor Life Sciences, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage.

Lento Bio

Company Details